Premium
Letter: immunotherapy in IBD patients in a SARS‐CoV‐2 endemic area
Author(s) -
Waggershauser Constanze H.,
TillackSchreiber Cornelia,
BerchtoldBenchieb Christine,
Szokodi Daniel,
Howaldt Stefanie,
Ochsenkühn Thomas
Publication year - 2020
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.15897
Subject(s) - medicine , covid-19 , immunotherapy , medline , inflammatory bowel diseases , virology , immunology , family medicine , inflammatory bowel disease , disease , infectious disease (medical specialty) , immune system , outbreak , political science , law
LINKED CONTENT This article is linked to Taxonera et al papers. To view these articles, visit https://doi.org/10.1111/apt.15804 and https://doi.org/10.1111/apt.15955
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom